Antidepressants help many patients, but residual symptoms are the norm. Cognitive symptoms often remain. Newer antidepressants or combination therapies should be considered to address remaining symptoms. And keep in mind—primary care clinicians can achieve results similar to those of psychiatrists in patients with major depressive disorder if they use measurement-based care.
Interactive case study
After completing this activity, participants should be better able to:
- Evaluate first-line agents for major depressive disorder (MDD) and agents for treatment-resistant depression
- Review the impact of residual symptoms of MDD, such as impaired cognition, and the importance of treating to target
- Outline strategies to address side effects and improve adherence in patients with MDD
Nurse practitioners and physician assistants
There are no prerequisites to participate in this activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.0, which are eligible for 1.0 pharmacology credits
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
This program has been reviewed and is approved for a maximum of 1.00 hour(s) of AAPA Category 1 CME credit by the PA Review Panel. Approval is valid for 1 year from the issue date of March 31, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program was cosupported by educational grants from AbbVie; Amgen; Astellas Scientific and Medical Affairs, Inc.; Genzyme, a Sanofi Company and Regeneron Pharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Sanofi US; Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck; and Teva Pharmaceuticals.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Thase: advisory/consultant: Acadia, Alkermes, Allergan, AstraZeneca, Cerecor, Fabre-Kramer, Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson, Lilly, Lundbeck, MedAvante, Merck, moksha8, Nestlé, Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda; grant/research support: Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest, Janssen, Intracellular, National Institute of Mental Health, Otsuka, Takeda; equity holdings: MedAvante; royalties: American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company; spouse's employment: Peloton Advantage.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Jody Walker, MS, Julie L. White, MS, and Jason Worcester, MD, of Boston University School of Medicine; Patti-Ann Collins, DNP, MSN, MBA, RN (Lead Nurse Planner), of Healthcare Advocacy Services; Mark Christiansen, PhD, PA-C, of the University of the Pacific; and Ruth Cohen and Margaret Inman of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Complete the interactive case study
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: March 31, 2017
Expiration date: March 30, 2018
Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+
© 2018 Practicing Clinicians Exchange. All Rights Reserved. CPCE90316-7a